AR107127A1 - REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES - Google Patents

REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES

Info

Publication number
AR107127A1
AR107127A1 ARP160103979A ARP160103979A AR107127A1 AR 107127 A1 AR107127 A1 AR 107127A1 AR P160103979 A ARP160103979 A AR P160103979A AR P160103979 A ARP160103979 A AR P160103979A AR 107127 A1 AR107127 A1 AR 107127A1
Authority
AR
Argentina
Prior art keywords
alkyl
mono
cycloalkyl
fluorine
hydroxy
Prior art date
Application number
ARP160103979A
Other languages
Spanish (es)
Inventor
Dr Stegmann Christian
Ring Sven
Dr Nubbemeyer Reinhard
Dr Lange Martin
Dr Bmer Ulf
Dr Steuber Holger
Dra Gnther Judith
Dra Schmidt Nicole
Dr Siebeneicher Holger
Dr Bothe Ulrich
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR107127A1 publication Critical patent/AR107127A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a indazoles sustituidos, procedimientos para su preparación, su uso solos o en combinaciones para el tratamiento y/o prevención de enfermedades, así como su uso para la preparación de medicamentos para el tratamiento y/o prevención de enfermedades, en especial para el tratamiento y/o la prevención de endometriosis, así como dolores asociados con endometriosis y otros síntomas asociados con endometriosis como dismenorrea, dispareunia, disuria y disquecia, de linfomas, artritis reumatoidea, espondiloartritis (en especial espondiloartritis psoriásica y enfermedad de Bechterew), lupus eritematoso, esclerosis múltiple, degeneración macular, EPOC, gota, enfermedades de hígado graso, insuficiencia insulínica, enfermedades tumorales y psoriasis. Reivindicación 1: Compuestos la fórmula general (1) en donde R¹ representa cloro u O-R⁴; R² representa alquilo C₁₋₈, que puede estar opcionalmente mono- o polisustituido, de modo independiente entre sí, igual o diferente, con uno a cinco átomos de flúor, uno a tres grupos hidroxi, oxetanilo, tetrahidrofuranilo, piranilo, un grupo oxo o un grupo alcoxi C₁₋₆, en donde el grupo alcoxi C₁₋₆ puede estar mono- a trisustituido con flúor o con hidroxilo o con C(=O)OH, C(=O)Me, C(=O)Et, C(=O)NH₂; R³ representa un grupo seleccionado de los restos del grupo de fórmulas (2), en donde R⁵ representa hidrógeno, cicloalquilo C₃₋₆ o alquilo C₁₋₆, en donde el alquilo C₁₋₆ puede estar opcionalmente mono- a trisustituido con ciclopropilo, ciano e hidroxi, en donde cada sustituyente sólo puede estar presente una vez o mono- a pentasustituido con átomos de flúor; R⁶ representa hidrógeno, flúor o metilo, o R³ representa un grupo seleccionado de los restos de fórmula (3) y (4), en donde R⁷ representa hidrógeno, cicloalquilo C₃₋₆, ciano, NH₂, NH(alquilo C₁₋₆), N(alquilo C₁₋₆)₂, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo, 4-metilpiperazin-1-ilo o alquilo C₁₋₆, en donde el alquilo C₁₋₆ puede estar opcionalmente mono- a trisustituido con ciclopropilo, ciano e hidroxi, en donde cada sustituyente solo puede estar presente una vez o mono- a pentasustituido con átomos de flúor; R⁸, R⁹, R¹⁰ representa hidrógeno, metilo o flúor, o R³ representa el compuesto de fórmula (5) en donde R¹¹ representa cicloalquilo C₃₋₆ o alquilo C₁₋₆, en donde el alquilo C₁₋₆ puede estar opcionalmente mono- a trisustituido con ciclopropilo, ciano e hidroxi, en donde cada sustituyente sélo puede estar presente una vez o mono- a pentasustituido con átomos de flúor; y R¹² representa hidrógeno, flúor o alquilo C₁₋₆, o R³ representa 6,7-dihidro-4H-pirazolo[5,1-c][1,4]oxazin-2-ilo, 5-metil-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-ilo o 4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-ilo o pirazolo[1,5-a]pirimidin-3-ilo, pirrolo[2,1-f][1,2,4]triazin-7-ilo, pirrolo[1,2-b]piridazin-7-ilo, tieno[2,3-b]pirazin-7-ilo, 5-aminopirazolo[1,5-a]pirimidin-3-ilo, 2-aminopirrolo[2,1-f][1,2,4]triazin-7-ilo, 2-aminopirrolo[1,2-b]piridazin-7-ilo, 2-aminotieno[2,3-b]pirazin-7-ilo; R⁴ representa heterociclilo saturado de 4 a 7 miembros o cicloalquilo C₃₋₇, en donde el radical heterociclilo saturado y el radical cicloalquilo C₃₋₇ pueden estar opcionalmente mono- o polisustituidos, igual o diferente, con alquilo C₁₋₆, trifluorometilo, 2,2,2-trifluoroetilo, ciclopropilo, C(=O)OH, alcoxi C₁₋₆, trifluorometoxi, 2,2,2-trifluoroetoxi, flúor, cloro, ciano, hidroxi, NH₂, NHRᵃ, N(Rᵃ)Rᵇ, o alquilo C₁₋₆, en donde alquilo C₁₋₆ puede estar opcionalmente mono- o polisustituido, igual o diferente con flúor, cloro, ciano, hidroxi, C(=O)O-alquilo C₁₋₆, C₍₌O₎OH, C₍₌O₎NH₂, C(=O)N(H)Rᵃ, C(=O)N(Rᵃ)Rᵇ, S-alquilo C₁₋₆, S(=O)₂-alquilo C₁₋₆, S(=O)₂NH₂, alcoxi C₁₋₆, trifluorometoxi, 2,2,2-trifluoroetoxi, NH₂, NHRᵃ, N(Rᵃ)Rᵇ, cicloalquilo C₃₋₇, tetrazol o heterociclilo saturado de 4 a 7 miembros, en donde cicloalquilo C₃₋₇, heteroarilo y heterociclilo saturado de 4 a 7 miembros opcionalmente mono- a tetrasustituido, igual o diferente, con flúor, alquilo C₁₋₄, hidroxi, C(=O)OH, trifluorometilo, 2,2,2-trifluoroetilo, metoxi, etoxi, trifluorometoxi, ciclopropilo, ciclopropilmetilo, metilsulfonilo, NH₂, NHRᵃ, N(Rᵃ)Rᵇ; Rᵃ representa alquilo C₁₋₆ o cicloalquilo C₃₋₇, en donde alquilo C₁₋₆ y cicloalquilo C₃₋₇ pueden estar opcionalmente mono- o polisustituidos, igual o diferente, con flúor, hidroxi, ciano, alquilo C₁₋₄, alcoxi C₁₋₄ o cicloalquilo C₃₋₇; Rᵇ representa alquilo C₁₋₆ o cicloalquilo C₃₋₇; y sus diastereómeros, enantiómeros, sus metabolitos, sus sales, sus solvatos o los solvatos de sus sales.This refers to substituted indazoles, procedures for their preparation, their use alone or in combinations for the treatment and / or prevention of diseases, as well as their use for the preparation of medicaments for the treatment and / or prevention of diseases, especially for the treatment and / or prevention of endometriosis, as well as pains associated with endometriosis and other symptoms associated with endometriosis such as dysmenorrhea, dyspareunia, dysuria and dysquecia, lymphomas, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bechterew's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver diseases, insulin insufficiency, tumor diseases and psoriasis. Claim 1: Compounds the general formula (1) wherein R¹ represents chlorine or O-R⁴; R² represents C₁₋₈ alkyl, which may be optionally mono- or polysubstituted, independently of one another, the same or different, with one to five fluorine atoms, one to three hydroxy groups, oxetanyl, tetrahydrofuranyl, pyranyl, an oxo group or a C₁₋₆ alkoxy group, wherein the C₁₋₆ alkoxy group may be mono- to trisubstituted with fluorine or with hydroxyl or with C (= O) OH, C (= O) Me, C (= O) Et, C (= O) NH₂; R³ represents a group selected from the moieties of the group of formulas (2), wherein R⁵ represents hydrogen, C₃₋₆ cycloalkyl or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl may optionally be mono- to trisubstituted with cyclopropyl, cyano and hydroxy, wherein each substituent may only be present once or mono- to pentas substituted with fluorine atoms; R⁶ represents hydrogen, fluorine or methyl, or R³ represents a group selected from the moieties of formula (3) and (4), wherein R⁷ represents hydrogen, C₃₋₆ cycloalkyl, cyano, NH₂, NH (C₁₋₆ alkyl), N (C₁₋₆ alkyl) ₂, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl may optionally be mono- to trisubstituted with cyclopropyl, cyano and hydroxy, where each substituent can only be present once or mono- to pentasubstituted with fluorine atoms; R⁸, R⁹, R¹⁰ represents hydrogen, methyl or fluorine, or R³ represents the compound of formula (5) wherein R¹¹ represents C₃₋₆ cycloalkyl or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl may optionally be mono- to trisubstituted with cyclopropyl, cyano and hydroxy, wherein each substituent may be present once or mono- to pentas substituted with fluorine atoms; and R¹² represents hydrogen, fluorine or C₁₋₆ alkyl, or R³ represents 6,7-dihydro-4H-pyrazolo [5,1-c] [1,4] oxazin-2-yl, 5-methyl-4,5, 6,7-tetrahydropyrazolo [1,5-a] pyrazin-2-yl or 4,5,6,7-tetrahydropyrazolo [1,5-a] pyrazin-2-yl or pyrazolo [1,5-a] pyrimidin- 3-yl, pyrrolo [2,1-f] [1,2,4] triazin-7-yl, pyrrolo [1,2-b] pyridazin-7-yl, thieno [2,3-b] pyrazin-7 -yl, 5-aminopyrazolo [1,5-a] pyrimidin-3-yl, 2-aminopyrrolo [2,1-f] [1,2,4] triazin-7-yl, 2-aminopyrrolo [1,2- b] pyridazin-7-yl, 2-aminothiene [2,3-b] pyrazin-7-yl; R⁴ represents 4 to 7 membered saturated heterocyclyl or C₃₋₇ cycloalkyl, wherein the saturated heterocyclyl radical and the C₃₋₇ cycloalkyl radical may optionally be mono- or polysubstituted, the same or different, with C₁₋₆ alkyl, trifluoromethyl, 2, 2,2-trifluoroethyl, cyclopropyl, C (= O) OH, C₁₋₆ alkoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, fluorine, chlorine, cyano, hydroxy, NH₂, NHRᵃ, N (Rᵃ) Rᵇ, or alkyl C₁₋₆, wherein C₁₋₆ alkyl may optionally be mono- or polysubstituted, the same or different with fluorine, chlorine, cyano, hydroxy, C (= O) O-C₁₋₆ alkyl, C₍₌O₎OH, C ₍₌O₎NH₂, C (= O) N (H) Rᵃ, C (= O) N (Rᵃ) Rᵇ, S-C₁₋₆ alkyl, S (= O) ₂-C₁₋₆ alkyl, S (= O) ₂NH₂, C₁₋₆ alkoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, NH₂, NHRᵃ, N (Rᵃ) Rᵇ, C₃₋₇ cycloalkyl, tetrazol or saturated 4-7 membered heterocyclyl, wherein C₃₋₇ cycloalkyl , heteroaryl and saturated heterocyclyl from 4 to 7 members os optionally mono- to tetrasubstituted, the same or different, with fluorine, C₁₋₄ alkyl, hydroxy, C (= O) OH, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, ethoxy, trifluoromethoxy, cyclopropyl, cyclopropylmethyl, methyl sulfonyl, NH₂, NHRᵃ, N (Rᵃ) Rᵇ; Rᵃ represents C₁₋₆ alkyl or C₃₋₇ cycloalkyl, wherein C₁₋₆ alkyl and C₃₋₇ cycloalkyl may optionally be mono- or polysubstituted, the same or different, with fluorine, hydroxy, cyano, C₁₋₄ alkyl, C₁₋ alkoxy ₄ or C₃₋₇ cycloalkyl; Rᵇ represents C₁₋₆ alkyl or C₃₋₇ cycloalkyl; and its diastereomers, enantiomers, its metabolites, its salts, its solvates or the solvates of its salts.

ARP160103979A 2015-12-22 2016-12-22 REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES AR107127A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15202240 2015-12-22

Publications (1)

Publication Number Publication Date
AR107127A1 true AR107127A1 (en) 2018-03-21

Family

ID=55068837

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103979A AR107127A1 (en) 2015-12-22 2016-12-22 REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES

Country Status (4)

Country Link
AR (1) AR107127A1 (en)
TW (1) TW201725202A (en)
UY (1) UY37048A (en)
WO (1) WO2017108744A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
ES2927104T3 (en) 2016-09-09 2022-11-02 Incyte Corp Pyrazolopyridine derivatives as modulators of HPK1 and uses thereof for the treatment of cancer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018060174A1 (en) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituted benzimidazoles, pharmaceutical preparations containing same, and use of same to produce drugs
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CA3082178A1 (en) * 2017-11-28 2019-06-06 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
CN108663441B (en) * 2017-12-30 2021-03-30 南京海融制药有限公司 Method for checking related substances of tacalcitol ointment
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (en) 2018-02-20 2022-11-30 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
TWI721483B (en) 2018-07-13 2021-03-11 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN112513027B (en) * 2018-08-17 2024-03-29 浙江海正药业股份有限公司 Indazole amine derivative, preparation method and medical application thereof
TW202028207A (en) 2018-09-25 2020-08-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
WO2020135513A1 (en) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 Compound serving as irak inhibitor
CN111499612B (en) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 Compound as IRAK inhibitor and preparation method and application thereof
CN111560012B (en) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 Compound as IRAK inhibitor
CN111821297A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
WO2020259626A1 (en) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 Imidazopyridine compound as irak4 inhibitor
US20230069104A1 (en) 2019-06-28 2023-03-02 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor
PE20220944A1 (en) * 2019-09-24 2022-05-31 Shanghai Meiyue Biotech Dev Co Ltd IRAQ INHIBITOR AND METHOD OF PREPARATION THEREOF AND USE THEREOF
CN113278017B (en) * 2021-05-27 2023-03-28 上海应用技术大学 Substituted indazoles, preparation method, application and composition containing same
CN113402499B (en) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 Sulfimide substituted indazole IRAK4 kinase inhibitor, preparation method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI667233B (en) * 2013-12-19 2019-08-01 德商拜耳製藥公司 Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors

Also Published As

Publication number Publication date
UY37048A (en) 2017-07-31
WO2017108744A1 (en) 2017-06-29
TW201725202A (en) 2017-07-16

Similar Documents

Publication Publication Date Title
AR107127A1 (en) REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CL2019002150A1 (en) Substituted 3-phenyl-4-amino-imidazo [4,5-c] pyridin-2-one and 7-phenyl-6-amino-purin-8-one derivatives, tyrosine kinase inhibitors, in particular bruton tyrosine kinase (btk ); compositions containing the compounds; and use for diseases such as cancer, autoimmune, inflammatory, and thromboembolic. (divisional request 201703073)
ECSP19047936A (en) IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES
PE20171307A1 (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
PE20170128A1 (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
UY35935A (en) NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND MODULATORS OF IRAK-4
NI201900060A (en) SMALL MOLECULE INHIBITORS OF THE KINASA JAK FAMILY
JP2015508075A5 (en)
AR085502A1 (en) TRICICLIC INHIBITORS OF USEFUL KINASES AS ANTI-BANKER AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY37926A (en) FORMULATIONS OF 6- (2-HYDROXI-2-METHYLPROPOXI) -4- (6- (6 - ((6-METOXIPIRIDIN-3-IL) METHYL) -3,6-DIAZABICICLO [3.1.1] HEPTAN-3-IL ) PIRIDIN-3-IL) PIRAZOLO [1,5-A] PIRIDINA-3-CARBONITRILE
AR100160A1 (en) 1H-PIRROLO [2,3-c] PIRIDIN-7 (6H) -ONAS AND PIRAZOLO [3,4-c] PIRIDIN-7 (6H) -ONAS AS BET PROTEIN INHIBITORS
EA201691484A1 (en) SALT AND SOLID FORM OF BTK INHIBITOR
CO2018005163A2 (en) Compound of [1,2,4] triazolo [1,5-a] pyrimidin-7-yl
CL2013000368A1 (en) Compounds derived from 6-cycloalkyl-1,5-dihydro-pyrazolo (3,4-d) pyrimidin-4-one, phosphodiesterase 9a inhibitors pde9a; pharmaceutical composition comprising one of the compounds; and use of the compounds and the pharmaceutical composition in the preparation of a medicament useful in the treatment of diseases of the snc.
PE20170321A1 (en) MITOGEN ACTIVATED PROTEIN KINASE (MNK) INTERACTION KINASE INHIBITORS AND RELATED METHODS
PE20170403A1 (en) IMIDAZO [4,5-c] QUINOLIN-2-ONA COMPOUNDS AND THEIR USE TO TREAT CANCER
UY37559A (en) PIRAZOLO [3,4-B] PIRIDINE AND PIRROLO [2,3-B] PIRIDINE AS INHIBITORS OF BRUTON TYPOSINE KINASE
CR20180172A (en) DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE CANCER TREATMENT
EA201891897A1 (en) 1,5-DIGIDRO-4H-PYRAZOLO [3,4-d] PYRIMIDIN-4-ONE and 1,5-DIHYDRO-4H-PYRAZOLO [4,3-c] PYRIDIN-4-ONE AS PDE1 INHIBITORS
PE20191236A1 (en) PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE OF THEM
AR093795A1 (en) PIRIDINUM OXIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES
PE20191349A1 (en) MNK INHIBITORS SUBSTITUTED WITH PIPERIDINE AND RELATED METHODS THEREOF
PE20170295A1 (en) IMIDAZOPYRIDAZINE COMPOUNDS
CL2019001669A1 (en) Pyrazolo [3,4-b] pyridines and imidazo [1,5-b] pyridazines as pde1 inhibitors.
PE20211246A1 (en) CYCLING COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure